首页 > 最新文献

Infectious Disease Reports最新文献

英文 中文
Risk Factors for Late HIV Presentation in Patients Treated at a Single Belgian Reference Centre from 2018 to 2022. 2018 年至 2022 年在比利时单一参考资料中心接受治疗的患者中出现艾滋病晚期症状的风险因素。
IF 3.2 Q2 INFECTIOUS DISEASES Pub Date : 2024-03-14 DOI: 10.3390/idr16020019
Damien Scaia, Karine Fombellida, Nathalie Maes, Majdouline El Moussaoui, Gilles Darcis

A late HIV diagnosis is associated with increased mortality and morbidity, increased healthcare costs and increased onward viral transmission. In this regard, we retrospectively analysed the characteristics of patients who presented for care at our centre from January 2018 to December 2022 to assess the proportion of patients and factors associated with late HIV presentation. We collected data from the Liège University Hospital database, and we used binary logistic regression models to analyse the impact of individuals' characteristics on late presentation. Among 167 participants, 38.3% were late presenters (LPs) (presenting for care with a CD4+ T-cell count < 350 cells/mm3 or after an AIDS-defining event), and 21.6% were late presenters with advanced disease (LPs-AD) (presenting for care with a CD4+ T-cell count < 200 cells/mm3 or after an AIDS-defining event). The risk of being an LPs-AD was increased in older individuals (OR on log-transformed age: 7.5) and individuals of sub-Saharan African origin compared to individuals of Belgian or other origin (ORs of 0.30 and 0.25, respectively). The results of this study suggest that broadening the focus beyond the previously common risk groups is essential to prevent late diagnosis.

晚期艾滋病诊断与死亡率和发病率增加、医疗成本增加和病毒传播增加有关。为此,我们回顾性分析了2018年1月至2022年12月在本中心就诊的患者特征,以评估与艾滋病晚期就诊相关的患者比例和因素。我们从列日大学医院数据库中收集了数据,并使用二元逻辑回归模型分析了个人特征对逾期就诊的影响。在167名参与者中,38.3%为晚期患者(LPs)(CD4+ T细胞计数小于350个细胞/立方毫米或发生艾滋病定义事件后就诊),21.6%为晚期患者(LPs-AD)(CD4+ T细胞计数小于200个细胞/立方毫米或发生艾滋病定义事件后就诊)。与比利时人或其他血统的人相比(OR 分别为 0.30 和 0.25),年龄较大的人(年龄对数转换后的 OR 为 7.5)和撒哈拉以南非洲血统的人成为 LPs-AD 的风险更高。这项研究的结果表明,要防止晚期诊断,就必须将重点扩大到以前常见的风险群体之外。
{"title":"Risk Factors for Late HIV Presentation in Patients Treated at a Single Belgian Reference Centre from 2018 to 2022.","authors":"Damien Scaia, Karine Fombellida, Nathalie Maes, Majdouline El Moussaoui, Gilles Darcis","doi":"10.3390/idr16020019","DOIUrl":"10.3390/idr16020019","url":null,"abstract":"<p><p>A late HIV diagnosis is associated with increased mortality and morbidity, increased healthcare costs and increased onward viral transmission. In this regard, we retrospectively analysed the characteristics of patients who presented for care at our centre from January 2018 to December 2022 to assess the proportion of patients and factors associated with late HIV presentation. We collected data from the Liège University Hospital database, and we used binary logistic regression models to analyse the impact of individuals' characteristics on late presentation. Among 167 participants, 38.3% were late presenters (LPs) (presenting for care with a CD4<sup>+</sup> T-cell count < 350 cells/mm<sup>3</sup> or after an AIDS-defining event), and 21.6% were late presenters with advanced disease (LPs-AD) (presenting for care with a CD4<sup>+</sup> T-cell count < 200 cells/mm<sup>3</sup> or after an AIDS-defining event). The risk of being an LPs-AD was increased in older individuals (OR on log-transformed age: 7.5) and individuals of sub-Saharan African origin compared to individuals of Belgian or other origin (ORs of 0.30 and 0.25, respectively). The results of this study suggest that broadening the focus beyond the previously common risk groups is essential to prevent late diagnosis.</p>","PeriodicalId":13579,"journal":{"name":"Infectious Disease Reports","volume":"16 2","pages":"239-248"},"PeriodicalIF":3.2,"publicationDate":"2024-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10961754/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140206790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An Aminoglycoside-Sparing Regimen with Double Beta-Lactam to Successfully Treat Granulicatella adiacens Prosthetic Aortic Valve Endocarditis-Time to Change Paradigm? 使用双β-内酰胺类药物的氨基糖苷类药物稀释疗法成功治疗阿迪阿克氏肉芽肿菌人工主动脉瓣心内膜炎--改变模式的时机到了吗?
IF 3.2 Q2 INFECTIOUS DISEASES Pub Date : 2024-03-14 DOI: 10.3390/idr16020020
Alberto Pagotto, Floriana Campanile, Paola Conti, Francesca Prataviera, Paola Della Siega, Sarah Flammini, Simone Giuliano, Luca Martini, Davide Pecori, Assunta Sartor, Maria Screm, Tosca Semenzin, Carlo Tascini

(1) Background: Granulicatella adiacens is a former nutritionally variant streptococci (NVS). NVS infective endocarditis (IE) is generally characterized by a higher rate of morbidity and mortality, partially due to difficulties in choosing the most adequate microbiological culture method and the most effective treatment strategy, and partially due to higher rates of complications, such as heart failure, peripheral septic embolism, and peri-valvular abscess, as well as a higher rate of valve replacement. Depending on the affected valve (native valve endocarditisNVE, or prosthetic valve endocarditisPVE), the American Heart Association (AHA) 2015 treatment guidelines (GLs) suggest penicillin G, ampicillin, or ceftriaxone plus gentamicin (2 weeks for NVE and up to 6 weeks for PVE), while vancomycin alone may be a reasonable alternative in patients who are intolerant of β-lactam therapy. The European Society of Cardiology (ESC) 2023 GLs recommend treating NVE with penicillin G, ceftriaxone, or vancomycin for 6 weeks, suggesting combined with an aminoglycoside (AG) for at least the first 2 weeks only for PVE; likewise, the same recommendations for IE due to Enterococcus faecalis. (2) Methods: Starting from the case of a 51-year-old man with G. adiacens aortic bio-prosthesis IE who was successfully treated with aortic valve replacement combined with double beta-lactams, an AG-sparing regimen, we performed microbiology tests in order to validate this potential treatment change. (3) Results: As for E. faecalis IE, we found that the combination of ampicillin plus cephalosporines (like ceftriaxone or ceftobiprole) showed a synergistic effect in vitro, probably due to wider binding to penicillin-binding proteins (PBPs), thus contributing to enhanced bacterial killing and good clinical outcome, as well as avoiding the risk of nephrotoxicity due to AG association therapy. (4) Conclusions: Further studies are required to confirm this hypothesis, but double beta-lactams and an adequate sourcecontrol could be a choice in treating G. adiacens IE.

(1) 背景:Granulicatella adiacens 是一种前营养变异链球菌(NVS)。NVS感染性心内膜炎(IE)的发病率和死亡率通常较高,部分原因是难以选择最适当的微生物培养方法和最有效的治疗策略,部分原因是并发症发生率较高,如心力衰竭、外周化脓性栓塞和瓣周脓肿,以及瓣膜置换率较高。根据受影响瓣膜的不同(原发瓣膜心内膜炎NVE或人工瓣膜心内膜炎PVE),美国心脏协会(AHA)2015年治疗指南(GLs)建议使用青霉素G、氨苄西林或头孢曲松加庆大霉素(NVE用药2周,PVE用药最多6周),而对于不能耐受β-内酰胺类药物治疗的患者,单用万古霉素可能是一个合理的替代方案。欧洲心脏病学会(ESC)2023 GLs 建议使用青霉素 G、头孢曲松或万古霉素治疗 NVE,疗程为 6 周,建议与氨基糖苷类药物(AG)联合治疗至少头 2 周,仅用于 PVE;同样,对于由粪肠球菌引起的 IE,也有相同的建议。(2)方法:一名 51 岁的男性主动脉生物假体感染 G. adiacens IE 患者成功接受了主动脉瓣置换术联合双β-内酰胺类药物治疗,这是一种节省 AG 的治疗方案,我们从该患者的病例出发,对其进行了微生物学检测,以验证这一潜在的治疗变化。(3)结果:对于粪肠球菌 IE,我们发现氨苄西林联合头孢菌素(如头孢曲松或头孢比洛)在体外显示出协同作用,这可能是由于与青霉素结合蛋白(PBPs)的结合范围更广,从而有助于增强杀灭细菌的能力,取得良好的临床疗效,并避免了 AG 联合疗法导致的肾毒性风险。(4)结论:这一假设还需要进一步的研究来证实,但双重β-内酰胺类药物和充分的源头控制可能是治疗 G. adiacens IE 的一种选择。
{"title":"An Aminoglycoside-Sparing Regimen with Double Beta-Lactam to Successfully Treat <i>Granulicatella adiacens</i> Prosthetic Aortic Valve Endocarditis-Time to Change Paradigm?","authors":"Alberto Pagotto, Floriana Campanile, Paola Conti, Francesca Prataviera, Paola Della Siega, Sarah Flammini, Simone Giuliano, Luca Martini, Davide Pecori, Assunta Sartor, Maria Screm, Tosca Semenzin, Carlo Tascini","doi":"10.3390/idr16020020","DOIUrl":"10.3390/idr16020020","url":null,"abstract":"<p><p>(1) Background: <i>Granulicatella adiacens</i> is a former nutritionally variant streptococci (NVS). NVS infective endocarditis (IE) is generally characterized by a higher rate of morbidity and mortality, partially due to difficulties in choosing the most adequate microbiological culture method and the most effective treatment strategy, and partially due to higher rates of complications, such as heart failure, peripheral septic embolism, and peri-valvular abscess, as well as a higher rate of valve replacement. Depending on the affected valve (native valve endocarditisNVE, or prosthetic valve endocarditisPVE), the American Heart Association (AHA) 2015 treatment guidelines (GLs) suggest penicillin G, ampicillin, or ceftriaxone <i>plus</i> gentamicin (2 weeks for NVE and up to 6 weeks for PVE), while vancomycin alone may be a reasonable alternative in patients who are intolerant of β-lactam therapy. The European Society of Cardiology (ESC) 2023 GLs recommend treating NVE with penicillin G, ceftriaxone, or vancomycin for 6 weeks, suggesting combined with an aminoglycoside (AG) for at least the first 2 weeks only for PVE; likewise, the same recommendations for IE due to Enterococcus faecalis. (2) Methods: Starting from the case of a 51-year-old man with <i>G. adiacens</i> aortic bio-prosthesis IE who was successfully treated with aortic valve replacement combined with double beta-lactams, an AG-sparing regimen, we performed microbiology tests in order to validate this potential treatment change. (3) Results: As for <i>E. faecalis</i> IE, we found that the combination of ampicillin <i>plus</i> cephalosporines (like ceftriaxone or ceftobiprole) showed a synergistic effect in vitro, probably due to wider binding to penicillin-binding proteins (PBPs), thus contributing to enhanced bacterial killing and good clinical outcome, as well as avoiding the risk of nephrotoxicity due to AG association therapy. (4) Conclusions: Further studies are required to confirm this hypothesis, but double beta-lactams and an adequate sourcecontrol could be a choice in treating <i>G. adiacens</i> IE.</p>","PeriodicalId":13579,"journal":{"name":"Infectious Disease Reports","volume":"16 2","pages":"249-259"},"PeriodicalIF":3.2,"publicationDate":"2024-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10961776/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140206785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Adverse Outcomes of Patients with Non-Ventilator-Associated Hospital-Acquired Pneumonia (nvHAP)-A Single Centre Cohort Study. 非呼吸机相关医院获得性肺炎 (nvHAP) 患者的不良预后--一项单中心队列研究。
IF 3.2 Q2 INFECTIOUS DISEASES Pub Date : 2024-03-13 DOI: 10.3390/idr16020018
Enrica Amodio, Peter W Schreiber, Mirjam Faes Hesse, Aline Wolfensberger

Non-ventilator associated hospital-acquired pneumonia (nvHAP) is a common nosocomial infection, but little is known about the outcomes of patients with nvHAP and the risk factors for adverse outcomes. In this retrospective study conducted in a Swiss tertiary care centre, adverse outcomes like in-hospital mortality, intensive care unit (ICU) admission, and mechanical ventilation, both all-cause and nvHAP-associated, were investigated. Of 244 patients with nvHAP, 72 (30%) died, 35 (14%) deaths were attributed to nvHAP. While 36 (15%) patients acquired nvHAP on the ICU, another 173 patients were eligible for ICU-transferral, and 76 (43.9%) needed ICU-admission. Of all patients hospitalized on the ICU 58 (51.8%) needed intubation due to nvHAP. Multivariable logistic regression analysis identified lower body mass index (OR per unit increase: 0.90, 95%CI: 0.82-0.98) and lower haemoglobin on admission (OR per unit in g/l increase: 0.98, 95%CI: 0.97-1.00) as patient specific factors independently associated with nvHAP-associated mortality. Given the frequency of nvHAP adverse outcomes, hospitals should evaluate increasing nvHAP prevention efforts, especially for patients at high risk for nvHAP mortality. To what extent pneumonia prevention interventions do lower nvHAP mortality in these patients is still to be evaluated.

非呼吸机相关医院获得性肺炎(nvHAP)是一种常见的院内感染,但人们对非呼吸机相关医院获得性肺炎患者的预后以及不良预后的风险因素知之甚少。这项在瑞士一家三级医疗中心进行的回顾性研究调查了院内死亡率、重症监护室(ICU)入院率和机械通气率等不良后果,包括全因和与 nvHAP 相关的不良后果。在 244 名 nvHAP 患者中,72 人(30%)死亡,其中 35 人(14%)的死亡归因于 nvHAP。有 36 名患者(15%)在重症监护病房感染了 nvHAP,另有 173 名患者符合重症监护病房转院条件,76 名患者(43.9%)需要入住重症监护病房。在重症监护室住院的所有患者中,有 58 人(51.8%)因 nvHAP 而需要插管。多变量逻辑回归分析发现,较低的体重指数(每单位增加的 OR 值:0.90,95%CI:0.82-0.98)和入院时较低的血红蛋白(以 g/l 为单位每单位增加的 OR 值:0.98,95%CI:0.97-1.00)是与 nvHAP 相关死亡率独立相关的患者特异性因素。考虑到 nvHAP 不良后果的发生频率,医院应评估加强 nvHAP 预防工作的力度,尤其是针对 nvHAP 死亡率高风险患者。肺炎预防干预措施能在多大程度上降低这些患者的 nvHAP 死亡率还有待评估。
{"title":"Adverse Outcomes of Patients with Non-Ventilator-Associated Hospital-Acquired Pneumonia (nvHAP)-A Single Centre Cohort Study.","authors":"Enrica Amodio, Peter W Schreiber, Mirjam Faes Hesse, Aline Wolfensberger","doi":"10.3390/idr16020018","DOIUrl":"10.3390/idr16020018","url":null,"abstract":"<p><p>Non-ventilator associated hospital-acquired pneumonia (nvHAP) is a common nosocomial infection, but little is known about the outcomes of patients with nvHAP and the risk factors for adverse outcomes. In this retrospective study conducted in a Swiss tertiary care centre, adverse outcomes like in-hospital mortality, intensive care unit (ICU) admission, and mechanical ventilation, both all-cause and nvHAP-associated, were investigated. Of 244 patients with nvHAP, 72 (30%) died, 35 (14%) deaths were attributed to nvHAP. While 36 (15%) patients acquired nvHAP on the ICU, another 173 patients were eligible for ICU-transferral, and 76 (43.9%) needed ICU-admission. Of all patients hospitalized on the ICU 58 (51.8%) needed intubation due to nvHAP. Multivariable logistic regression analysis identified lower body mass index (OR per unit increase: 0.90, 95%CI: 0.82-0.98) and lower haemoglobin on admission (OR per unit in g/l increase: 0.98, 95%CI: 0.97-1.00) as patient specific factors independently associated with nvHAP-associated mortality. Given the frequency of nvHAP adverse outcomes, hospitals should evaluate increasing nvHAP prevention efforts, especially for patients at high risk for nvHAP mortality. To what extent pneumonia prevention interventions do lower nvHAP mortality in these patients is still to be evaluated.</p>","PeriodicalId":13579,"journal":{"name":"Infectious Disease Reports","volume":"16 2","pages":"228-238"},"PeriodicalIF":3.2,"publicationDate":"2024-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10961785/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140206784","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tackling Infectious Diseases with Rapid Molecular Diagnosis and Innovative Prevention. 通过快速分子诊断和创新性预防应对传染病。
IF 3.2 Q2 INFECTIOUS DISEASES Pub Date : 2024-03-05 DOI: 10.3390/idr16020017
Rabeea F Omar, Maurice Boissinot, Ann Huletsky, Michel G Bergeron

Infectious diseases (IDs) are a leading cause of death. The diversity and adaptability of microbes represent a continuing risk to health. Combining vision with passion, our transdisciplinary medical research team has been focussing its work on the better management of infectious diseases for saving human lives over the past five decades through medical discoveries and innovations that helped change the practice of medicine. The team used a multiple-faceted and integrated approach to control infectious diseases through fundamental discoveries and by developing innovative prevention tools and rapid molecular diagnostic tests to fulfill the various unmet needs of patients and health professionals in the field of ID. In this article, as objectives, we put in context two main research areas of ID management: innovative infection prevention that is woman-controlled, and the rapid molecular diagnosis of infection and resistance. We also explain how our transdisciplinary approach encompassing specialists from diverse fields ranging from biology to engineering was instrumental in achieving success. Furthermore, we discuss our vision of the future for translational research to better tackle IDs.

传染病(IDs)是导致死亡的主要原因。微生物的多样性和适应性对健康构成了持续的威胁。我们的跨学科医学研究团队将远见与激情相结合,在过去的五十年里,通过医学发现和创新,将工作重点放在更好地控制传染病上,以挽救人类的生命。该团队采用多方面的综合方法,通过基础发现、开发创新型预防工具和快速分子诊断检测来控制传染病,以满足患者和卫生专业人员在 ID 领域尚未得到满足的各种需求。在本文中,作为目标,我们将介绍 ID 管理的两个主要研究领域:由妇女控制的创新型感染预防,以及感染和耐药性的快速分子诊断。我们还解释了从生物学到工程学等不同领域的专家如何通过跨学科方法取得成功。此外,我们还讨论了我们对未来转化研究的愿景,以更好地应对 ID。
{"title":"Tackling Infectious Diseases with Rapid Molecular Diagnosis and Innovative Prevention.","authors":"Rabeea F Omar, Maurice Boissinot, Ann Huletsky, Michel G Bergeron","doi":"10.3390/idr16020017","DOIUrl":"10.3390/idr16020017","url":null,"abstract":"<p><p>Infectious diseases (IDs) are a leading cause of death. The diversity and adaptability of microbes represent a continuing risk to health. Combining vision with passion, our transdisciplinary medical research team has been focussing its work on the better management of infectious diseases for saving human lives over the past five decades through medical discoveries and innovations that helped change the practice of medicine. The team used a multiple-faceted and integrated approach to control infectious diseases through fundamental discoveries and by developing innovative prevention tools and rapid molecular diagnostic tests to fulfill the various unmet needs of patients and health professionals in the field of ID. In this article, as objectives, we put in context two main research areas of ID management: innovative infection prevention that is woman-controlled, and the rapid molecular diagnosis of infection and resistance. We also explain how our transdisciplinary approach encompassing specialists from diverse fields ranging from biology to engineering was instrumental in achieving success. Furthermore, we discuss our vision of the future for translational research to better tackle IDs.</p>","PeriodicalId":13579,"journal":{"name":"Infectious Disease Reports","volume":"16 2","pages":"216-227"},"PeriodicalIF":3.2,"publicationDate":"2024-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10961803/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140206791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pulmonary Involvement in Recurrent Respiratory Papillomatosis: A Systematic Review. 复发性呼吸道乳头状瘤病的肺部受累:系统回顾
IF 3.2 Q2 INFECTIOUS DISEASES Pub Date : 2024-02-28 DOI: 10.3390/idr16020016
Illari Sechi, Narcisa Muresu, Biagio Di Lorenzo, Laura Saderi, Mariangela Puci, Stefano Aliberti, Ivana Maida, Michele Mondoni, Andrea Piana, Giovanni Sotgiu

Recurrent respiratory papillomatosis (RRP) is a non-malignant disease, characterized by the production of wart-like growths in the respiratory tract, affecting both young people and adults (juvenile-onset recurrent respiratory papillomatosis, JORRP, and adult-onset recurrent respiratory papillomatosis, AORRP, respectively). Infection caused by human papillomavirus (HPV) is known as the main factor involved in RRP development. Complications of RRP may rarely occur, including lung involvement and malignant transformation. The present systematic review aimed to evaluate the prevalence of severe complications, such as lung involvement and lung tumor in JORRP and AORRP patients, and assess the role of HPV genotypes in the progression of disease severity following the guideline for reporting systematic reviews and meta-analysis (PRISMA Statement). A total of 378 studies were found on PubMed and Scopus using the following MESH terms: "recurrent respiratory papillomatosis and lung tumor" and "pulmonary tumor and recurrent respiratory papillomatosis". Basing on inclusion and exclusion criteria, a total of 11 studies were included in the systematic review. We found a pooled prevalence of 8% (95% CI: 4-14%; I2: 87.5%) for lung involvement in RRP patients. In addition, we found a pooled risk difference of 5% in lung involvement between JORRP and AORRP (95% CI: -7-18%; I2: 85.6%, p-value: 0.41). Among patients with lung involvement, we observed a pooled prevalence of lung tumor of 4% (95% CI:1-7%; I2: 67.1%) and a pooled prevalence mortality for this group of 4% (95% CI:2-6%; I2: 0%). Overall, the positivity rate for HPV-6 and -11 in patients with RRP was 91%. Considering only cases with pulmonary involvement, the pooled prevalence for HPV-11 was 21% (95% CI: 5-45%; I2: 77.2%). Our results evidenced a low/middle risk of pulmonary involvement and lung tumor in JORRP and AORRP patients, with an increased risk for HPV-11-positive patients. Further studies should be performed to improve knowledge and adopt preventive measures to contrast the progression to severe diseases in RRP patients.

复发性呼吸道乳头状瘤病(RRP)是一种非恶性疾病,其特征是在呼吸道内产生疣状增生,青少年和成年人均可患病(分别为青少年型复发性呼吸道乳头状瘤病和成人型复发性呼吸道乳头状瘤病)。人类乳头瘤病毒(HPV)感染是导致复发性呼吸道乳头瘤病的主要因素。RRP很少会出现并发症,包括肺部受累和恶性转化。本系统综述旨在根据系统综述和荟萃分析报告指南(PRISMA声明),评估JORRP和AORRP患者肺部受累和肺部肿瘤等严重并发症的发生率,并评估HPV基因型在疾病严重程度进展中的作用。使用以下 MESH 术语在 PubMed 和 Scopus 上共找到 378 项研究:"复发性呼吸道乳头状瘤病和肺肿瘤 "和 "肺肿瘤和复发性呼吸道乳头状瘤病"。根据纳入和排除标准,共有 11 项研究被纳入系统综述。我们发现,RRP 患者肺部受累的汇总患病率为 8%(95% CI:4-14%;I2:87.5%)。此外,我们还发现 JORRP 和 AORRP 肺部受累的汇总风险差异为 5%(95% CI:-7-18%;I2:85.6%,P 值:0.41)。在肺部受累的患者中,我们观察到肺部肿瘤的汇总患病率为 4% (95% CI:1-7%; I2: 67.1%),这组患者的汇总死亡率为 4% (95% CI:2-6%; I2: 0%)。总体而言,RRP 患者的 HPV-6 和 -11 阳性率为 91%。如果只考虑肺部受累的病例,HPV-11的汇总感染率为21%(95% CI:5-45%;I2:77.2%)。我们的研究结果表明,JORRP 和 AORRP 患者肺部受累和肺部肿瘤的风险较低/中等,HPV-11 阳性患者的风险较高。应开展进一步的研究,以增进对 RRP 患者的了解并采取预防措施,避免其发展为严重疾病。
{"title":"Pulmonary Involvement in Recurrent Respiratory Papillomatosis: A Systematic Review.","authors":"Illari Sechi, Narcisa Muresu, Biagio Di Lorenzo, Laura Saderi, Mariangela Puci, Stefano Aliberti, Ivana Maida, Michele Mondoni, Andrea Piana, Giovanni Sotgiu","doi":"10.3390/idr16020016","DOIUrl":"10.3390/idr16020016","url":null,"abstract":"<p><p>Recurrent respiratory papillomatosis (RRP) is a non-malignant disease, characterized by the production of wart-like growths in the respiratory tract, affecting both young people and adults (juvenile-onset recurrent respiratory papillomatosis, JORRP, and adult-onset recurrent respiratory papillomatosis, AORRP, respectively). Infection caused by human papillomavirus (HPV) is known as the main factor involved in RRP development. Complications of RRP may rarely occur, including lung involvement and malignant transformation. The present systematic review aimed to evaluate the prevalence of severe complications, such as lung involvement and lung tumor in JORRP and AORRP patients, and assess the role of HPV genotypes in the progression of disease severity following the guideline for reporting systematic reviews and meta-analysis (PRISMA Statement). A total of 378 studies were found on PubMed and Scopus using the following MESH terms: \"recurrent respiratory papillomatosis and lung tumor\" and \"pulmonary tumor and recurrent respiratory papillomatosis\". Basing on inclusion and exclusion criteria, a total of 11 studies were included in the systematic review. We found a pooled prevalence of 8% (95% CI: 4-14%; I<sup>2</sup>: 87.5%) for lung involvement in RRP patients. In addition, we found a pooled risk difference of 5% in lung involvement between JORRP and AORRP (95% CI: -7-18%; I<sup>2</sup>: 85.6%, <i>p</i>-value: 0.41). Among patients with lung involvement, we observed a pooled prevalence of lung tumor of 4% (95% CI:1-7%; I<sup>2</sup>: 67.1%) and a pooled prevalence mortality for this group of 4% (95% CI:2-6%; I<sup>2</sup>: 0%). Overall, the positivity rate for HPV-6 and -11 in patients with RRP was 91%. Considering only cases with pulmonary involvement, the pooled prevalence for HPV-11 was 21% (95% CI: 5-45%; I<sup>2</sup>: 77.2%). Our results evidenced a low/middle risk of pulmonary involvement and lung tumor in JORRP and AORRP patients, with an increased risk for HPV-11-positive patients. Further studies should be performed to improve knowledge and adopt preventive measures to contrast the progression to severe diseases in RRP patients.</p>","PeriodicalId":13579,"journal":{"name":"Infectious Disease Reports","volume":"16 2","pages":"200-215"},"PeriodicalIF":3.2,"publicationDate":"2024-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10961772/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140206788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Radiological Explorations of Patients with Upper or Febrile Urinary Tract Infection. 上尿路感染或发热尿路感染患者的放射学检查。
IF 3.2 Q2 INFECTIOUS DISEASES Pub Date : 2024-02-23 DOI: 10.3390/idr16020015
Katia Vanolli, Mike Libasse Jost, Olivier Clerc, Daniel Genné, Gregor John

Recent European Association of Urology (EAU) guidelines and a clinical prediction rule developed by Van Nieuwkoop et al. suggest simple criteria for performing radiological imaging for patients with a febrile urinary tract infection (UTI). We analysed the records of patients with a UTI from four hospitals in Switzerland. Of 107 UTI patients, 58% underwent imaging and 69% (95%CI: 59-77%) and 64% (95%CI: 54-73%) of them were adequately managed according to Van Nieuwkoop's clinical rule and EAU guidelines, respectively. However, only 47% (95%CI: 33-61%) and 57% (95%CI: 44-69%) of the imaging performed would have been recommended according to their respective rules. Clinically significant imaging findings were associated with a history of urolithiasis (OR = 11.8; 95%CI: 3.0-46.5), gross haematuria (OR = 5.9; 95%CI: 1.6-22.1) and known urogenital anomalies (OR = 5.7; 95%CI: 1.8-18.2). Moreover, six of 16 (38%) patients with a clinically relevant abnormality displayed none of the criteria requiring imaging according to Van Nieuwkoop's rule or EAU guidelines. Thus, adherence to imaging guidelines was suboptimal, especially when imaging was not recommended. However, additional factors associated with clinically significant findings suggest the need for a new, efficient clinical prediction rule.

欧洲泌尿学协会(EAU)最近的指导方针和 Van Nieuwkoop 等人制定的临床预测规则提出了对发热性尿路感染(UTI)患者进行放射成像检查的简单标准。我们分析了瑞士四家医院的尿路感染患者病历。在 107 名 UTI 患者中,58% 接受了影像学检查,69%(95%CI:59-77%)和 64%(95%CI:54-73%)的患者分别根据 Van Nieuwkoop 的临床规则和 EAU 指南进行了适当处理。然而,只有47%(95%CI:33-61%)和57%(95%CI:44-69%)的成像结果是根据各自的规则建议进行的。具有临床意义的成像结果与尿路结石病史(OR = 11.8;95%CI:3.0-46.5)、毛血尿(OR = 5.9;95%CI:1.6-22.1)和已知的泌尿生殖系统异常(OR = 5.7;95%CI:1.8-18.2)有关。此外,在 16 名有临床相关异常的患者中,有 6 名患者(38%)不符合 Van Nieuwkoop 规则或 EAU 指南中要求进行影像学检查的标准。因此,对影像学指南的遵守情况并不理想,尤其是在不建议进行影像学检查的情况下。然而,与具有临床意义的检查结果相关的其他因素表明,需要一种新的、有效的临床预测规则。
{"title":"Radiological Explorations of Patients with Upper or Febrile Urinary Tract Infection.","authors":"Katia Vanolli, Mike Libasse Jost, Olivier Clerc, Daniel Genné, Gregor John","doi":"10.3390/idr16020015","DOIUrl":"10.3390/idr16020015","url":null,"abstract":"<p><p>Recent European Association of Urology (EAU) guidelines and a clinical prediction rule developed by Van Nieuwkoop et al. suggest simple criteria for performing radiological imaging for patients with a febrile urinary tract infection (UTI). We analysed the records of patients with a UTI from four hospitals in Switzerland. Of 107 UTI patients, 58% underwent imaging and 69% (95%CI: 59-77%) and 64% (95%CI: 54-73%) of them were adequately managed according to Van Nieuwkoop's clinical rule and EAU guidelines, respectively. However, only 47% (95%CI: 33-61%) and 57% (95%CI: 44-69%) of the imaging performed would have been recommended according to their respective rules. Clinically significant imaging findings were associated with a history of urolithiasis (OR = 11.8; 95%CI: 3.0-46.5), gross haematuria (OR = 5.9; 95%CI: 1.6-22.1) and known urogenital anomalies (OR = 5.7; 95%CI: 1.8-18.2). Moreover, six of 16 (38%) patients with a clinically relevant abnormality displayed none of the criteria requiring imaging according to Van Nieuwkoop's rule or EAU guidelines. Thus, adherence to imaging guidelines was suboptimal, especially when imaging was not recommended. However, additional factors associated with clinically significant findings suggest the need for a new, efficient clinical prediction rule.</p>","PeriodicalId":13579,"journal":{"name":"Infectious Disease Reports","volume":"16 2","pages":"189-199"},"PeriodicalIF":3.2,"publicationDate":"2024-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10961809/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140206789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Assessment of Monkeypox (MPOX) Knowledge and Vaccination Intention among Health and Life Sciences Students in Algeria: A Cross-Sectional Study. 阿尔及利亚健康和生命科学专业学生对猴痘 (MPOX) 知识和疫苗接种意向的评估:横断面研究。
IF 3.2 Q2 INFECTIOUS DISEASES Pub Date : 2024-02-22 DOI: 10.3390/idr16020013
Mohamed Lounis, Ahmed Hamimes, Ali Dahmani

Monkeypox (MPOX) is a viral zoonotic disease affecting endemically the Central and Western regions of Africa. The ongoing outbreak in non-endemic countries has made this disease a global concern. While no cases have been reported in Algeria, it is important to raise awareness about the disease to prepare for a potential outbreak, especially in light of the cases reported in neighboring Middle East and North African (MENA) countries. This study aimed to evaluate the knowledge and attitude of Algerian Health and Life Sciences students toward MPOX and its vaccine through an anonymous online survey. A total of 196 students participated in this study. Students of medicine (64.3%), females (85.7%), and those under 20 years of age (55.1%) were the most represented. The results revealed a low level of knowledge represented by a score of only 42.8% for correct answers with multiple gaps in epidemiology, etiology, and clinical manifestations of MPOX. Students of veterinary sciences showed the highest levels of knowledge (OR: 6.71; CI95%: 1.23-36.77), while those aged between 20 and 30 years old (OR: 0.11; CI95%: 0.02-0.79) and those vaccinated against seasonal flu (OR: 0.42; CI95%: 0.21-0.85) were associated with low levels of knowledge. Regarding MPOX vaccination, the study found a moderate level of acceptance (48.5%) among the surveyed students with Natural and Life Sciences students and those having a high vaccine conspiracy belief score (VCBS) showing the lowest level of acceptance. These findings highlight the need for educational programs and intensified public awareness campaigns to improve knowledge about MPOX and emphasize the importance of vaccination in preventing outbreaks and overcoming vaccine reluctance.

猴痘(MPOX)是一种病毒性人畜共患病,主要流行于非洲中部和西部地区。该疾病在非流行国家的持续爆发已成为全球关注的问题。虽然阿尔及利亚尚未报告病例,但必须提高对该疾病的认识,为可能爆发的疫情做好准备,特别是考虑到中东和北非邻国(MENA)报告的病例。本研究旨在通过匿名在线调查评估阿尔及利亚健康和生命科学专业学生对 MPOX 及其疫苗的认识和态度。共有 196 名学生参与了这项研究。其中医学专业学生(64.3%)、女生(85.7%)和 20 岁以下学生(55.1%)最多。结果显示,学生的知识水平较低,正确答案仅占 42.8%,在 MPOX 的流行病学、病因学和临床表现方面存在多项空白。兽医科学专业学生的知识水平最高(OR:6.71;CI95%:1.23-36.77),而年龄在 20-30 岁之间的学生(OR:0.11;CI95%:0.02-0.79)和接种过季节性流感疫苗的学生(OR:0.42;CI95%:0.21-0.85)的知识水平较低。关于 MPOX 疫苗接种,研究发现受访学生的接受程度(48.5%)适中,其中自然科学和生命科学学生以及疫苗阴谋信念得分(VCBS)较高的学生的接受程度最低。这些发现突出表明,有必要开展教育计划和加强公众宣传活动,以提高对 MPOX 的认识,并强调接种疫苗对预防疾病爆发和克服疫苗排斥的重要性。
{"title":"Assessment of Monkeypox (MPOX) Knowledge and Vaccination Intention among Health and Life Sciences Students in Algeria: A Cross-Sectional Study.","authors":"Mohamed Lounis, Ahmed Hamimes, Ali Dahmani","doi":"10.3390/idr16020013","DOIUrl":"10.3390/idr16020013","url":null,"abstract":"<p><p>Monkeypox (MPOX) is a viral zoonotic disease affecting endemically the Central and Western regions of Africa. The ongoing outbreak in non-endemic countries has made this disease a global concern. While no cases have been reported in Algeria, it is important to raise awareness about the disease to prepare for a potential outbreak, especially in light of the cases reported in neighboring Middle East and North African (MENA) countries. This study aimed to evaluate the knowledge and attitude of Algerian Health and Life Sciences students toward MPOX and its vaccine through an anonymous online survey. A total of 196 students participated in this study. Students of medicine (64.3%), females (85.7%), and those under 20 years of age (55.1%) were the most represented. The results revealed a low level of knowledge represented by a score of only 42.8% for correct answers with multiple gaps in epidemiology, etiology, and clinical manifestations of MPOX. Students of veterinary sciences showed the highest levels of knowledge (OR: 6.71; CI95%: 1.23-36.77), while those aged between 20 and 30 years old (OR: 0.11; CI95%: 0.02-0.79) and those vaccinated against seasonal flu (OR: 0.42; CI95%: 0.21-0.85) were associated with low levels of knowledge. Regarding MPOX vaccination, the study found a moderate level of acceptance (48.5%) among the surveyed students with Natural and Life Sciences students and those having a high vaccine conspiracy belief score (VCBS) showing the lowest level of acceptance. These findings highlight the need for educational programs and intensified public awareness campaigns to improve knowledge about MPOX and emphasize the importance of vaccination in preventing outbreaks and overcoming vaccine reluctance.</p>","PeriodicalId":13579,"journal":{"name":"Infectious Disease Reports","volume":"16 2","pages":"170-180"},"PeriodicalIF":3.2,"publicationDate":"2024-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10961808/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140206786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Prevalence, Risk Factors, and Antimicrobial Resistance Determinants of Helicobacter pylori Detected in Dyspeptic Patients in North-Central Bangladesh. 孟加拉国中北部消化不良患者幽门螺旋杆菌的流行率、风险因素和抗菌药耐药性决定因素。
IF 3.2 Q2 INFECTIOUS DISEASES Pub Date : 2024-02-22 DOI: 10.3390/idr16020014
Syeda Jannatul Ferdaus, Shyamal Kumar Paul, Syeda Anjuman Nasreen, Nazia Haque, Mohammad Sadekuzzaman, Mohammad Reazul Karim, Syed Mahmudul Islam, Abdullah Al Mamun, Fardousi Akter Sathi, Proma Basak, Rifat Binte Nahid, Suraiya Aktar, Nobumichi Kobayashi

Chronic infection of Helicobacter pylori represents a key factor in the etiology of gastrointestinal diseases, with high endemicity in South Asia. The present study aimed to determine the prevalence of H. pylori among dyspeptic patients in north-central Bangladesh (Mymensingh) and analyze risk factors of infection and antimicrobial resistance (AMR) determinants in the pathogen. Endoscopic gastrointestinal biopsy samples were collected from dyspeptic patients for a one-year period from March 2022 and were checked for the presence of H. pylori via the rapid urease test and PCR and further analyzed for the status of virulence factors vacA/cagA and genetic determinants related to AMR via PCR with direct sequencing or RFLP. Among a total of 221 samples collected, 80 (36%) were positive for H. pylori, with the vacA+/cagA+ genotype being detected in almost half of them. H. pylori was most prevalent in the age group of 41-50-year-olds, with it being more common in males and rural residents with a lower economic status and using nonfiltered water, though the rates of these factors were not significantly different from those of the H. pylori-negative group. Relatively higher frequency was noted for the A2147G mutation in 23S rRNA, related to clarithromycin resistance (18%, 7/39). Amino acid substitutions in PBP-1A (T556S) and GyrA (N87K and D91N) and a 200 bp deletion in rdxA were detected in samples from some patients with recurrence after treatment with amoxicillin, levofloxacin, and metronidazole, respectively. The present study describes the epidemiological features of H. pylori infection in the area outside the capital in Bangladesh, revealing the spread of AMR-associated mutations.

幽门螺杆菌慢性感染是胃肠道疾病病因中的一个关键因素,在南亚地区流行率很高。本研究旨在确定孟加拉国中北部(迈门辛格)消化不良患者中幽门螺杆菌的感染率,并分析感染的风险因素和病原体的抗菌药耐药性(AMR)决定因素。从 2022 年 3 月起的一年时间里,收集了消化不良患者的内窥镜胃肠道活检样本,通过快速尿素酶测试和 PCR 检查是否存在幽门螺杆菌,并通过 PCR 直接测序或 RFLP 进一步分析毒力因子 vacA/cagA 的状态以及与 AMR 相关的基因决定因素。在收集到的 221 份样本中,80 份(36%)幽门螺杆菌检测呈阳性,其中近一半检测出 vacA+/cagA+ 基因型。幽门螺杆菌在 41-50 岁年龄组的发病率最高,在男性、经济地位较低的农村居民和使用未经过滤的水的人群中更为常见,但这些因素与幽门螺杆菌阴性组的发病率并无明显差异。23S rRNA 中与克拉霉素耐药性有关的 A2147G 突变的频率相对较高(18%,7/39)。在一些使用阿莫西林、左氧氟沙星和甲硝唑治疗后复发的患者样本中,分别检测到了 PBP-1A (T556S)和 GyrA (N87K 和 D91N)的氨基酸置换以及 rdxA 的 200 bp 缺失。本研究描述了孟加拉国首都以外地区幽门螺杆菌感染的流行病学特征,揭示了 AMR 相关突变的传播。
{"title":"The Prevalence, Risk Factors, and Antimicrobial Resistance Determinants of <i>Helicobacter pylori</i> Detected in Dyspeptic Patients in North-Central Bangladesh.","authors":"Syeda Jannatul Ferdaus, Shyamal Kumar Paul, Syeda Anjuman Nasreen, Nazia Haque, Mohammad Sadekuzzaman, Mohammad Reazul Karim, Syed Mahmudul Islam, Abdullah Al Mamun, Fardousi Akter Sathi, Proma Basak, Rifat Binte Nahid, Suraiya Aktar, Nobumichi Kobayashi","doi":"10.3390/idr16020014","DOIUrl":"10.3390/idr16020014","url":null,"abstract":"<p><p>Chronic infection of <i>Helicobacter pylori</i> represents a key factor in the etiology of gastrointestinal diseases, with high endemicity in South Asia. The present study aimed to determine the prevalence of <i>H. pylori</i> among dyspeptic patients in north-central Bangladesh (Mymensingh) and analyze risk factors of infection and antimicrobial resistance (AMR) determinants in the pathogen. Endoscopic gastrointestinal biopsy samples were collected from dyspeptic patients for a one-year period from March 2022 and were checked for the presence of <i>H. pylori</i> via the rapid urease test and PCR and further analyzed for the status of virulence factors <i>vacA</i>/<i>cagA</i> and genetic determinants related to AMR via PCR with direct sequencing or RFLP. Among a total of 221 samples collected, 80 (36%) were positive for <i>H. pylori</i>, with the <i>vacA</i>+/<i>cagA</i>+ genotype being detected in almost half of them. <i>H. pylori</i> was most prevalent in the age group of 41-50-year-olds, with it being more common in males and rural residents with a lower economic status and using nonfiltered water, though the rates of these factors were not significantly different from those of the <i>H. pylori</i>-negative group. Relatively higher frequency was noted for the A2147G mutation in 23S rRNA, related to clarithromycin resistance (18%, 7/39). Amino acid substitutions in PBP-1A (T556S) and GyrA (N87K and D91N) and a 200 bp deletion in <i>rdxA</i> were detected in samples from some patients with recurrence after treatment with amoxicillin, levofloxacin, and metronidazole, respectively. The present study describes the epidemiological features of <i>H. pylori</i> infection in the area outside the capital in Bangladesh, revealing the spread of AMR-associated mutations.</p>","PeriodicalId":13579,"journal":{"name":"Infectious Disease Reports","volume":"16 2","pages":"181-188"},"PeriodicalIF":3.2,"publicationDate":"2024-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10961801/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140206792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hemophagocytic Lymphohistiocytosis (HLH) in Patients with Tick-Borne Illness: A Scoping Review of 98 Cases. 蜱传疾病患者的嗜血细胞淋巴组织细胞增多症(HLH):对 98 例病例的范围审查。
IF 3.4 Q2 INFECTIOUS DISEASES Pub Date : 2024-02-21 DOI: 10.3390/idr16020012
Dorde Jevtic, Marilia Dagnon da Silva, Alberto Busmail Haylock, Charles W Nordstrom, Stevan Oluic, Nikola Pantic, Milan Nikolajevic, Nikola Nikolajevic, Magdalena Kotseva, Igor Dumic

Hemophagocytic lymphohistiocytosis (HLH) secondary to tick-borne infections is a rare but potentially life-threatening syndrome. We performed a scoping review according to PRISMA guidelines to systematically analyze the existing literature on the topic. A total of 98 patients were included, with a mean age of 43.7 years, of which 64% were men. Most cases, 31%, were reported from the USA. Immunosuppression was present in 21.4%, with the most common cause being previous solid organ transplantation. Constitutional symptoms were the most common, observed in 83.7% of the patients, while fever was reported in 70.4% of cases. Sepsis was present in 27.6%. The most common laboratory abnormalities in this cohort were thrombocytopenia in 81.6% of patients, while anemia, leukopenia, and leukocytosis were observed in 75.5%, 55.1%, and 10.2%, respectively. Liver enzyme elevation was noted in 63.3% of cases. The H-score was analyzed in 64 patients, with the mean value being 209, and bone marrow analysis was performed in 61.2% of patients. Ehrlichia spp. was the main isolated agent associated with HLH in 45.9%, followed by Rickettsia spp. in 14.3% and Anaplasma phagocytophilum in 12.2%. Notably, no patient with Powassan virus infection or Lyme borreliosis developed HLH. The most common complications were acute kidney injury (AKI) in 35.7% of patients, shock with multiple organ dysfunction in 22.5%, encephalopathy/seizure in 20.4%, respiratory failure in 16.3%, and cardiac complications in 7.1% of patients. Treatment included antibiotic therapy alone in 43.9%, while 5.1% of patients were treated with immunosuppressants alone. Treatment with both antibiotics and immunosuppressants was used in 51% of patients. Appropriate empiric antibiotics were used in 62.2%. In 43.9% of cases of HLH due to tick-borne disease, patients received only antimicrobial therapy, and 88.4% of those recovered completely without the need for immunosuppressive therapy. The mortality rate in our review was 16.3%, and patients who received inappropriate or delayed empiric therapy had a worse outcome. Hence, we suggest empiric antibiotic treatment in patients who are suspected of having HLH due to tick-borne disease or in whom diagnostic uncertainty persists due to diagnostic delay in order to minimize mortality.

继发于蜱虫感染的嗜血细胞淋巴组织细胞增多症(HLH)是一种罕见但可能危及生命的综合征。我们根据 PRISMA 指南进行了一次范围界定审查,系统分析了有关该主题的现有文献。共纳入 98 例患者,平均年龄为 43.7 岁,其中 64% 为男性。大多数病例(31%)来自美国。21.4%的患者存在免疫抑制,最常见的原因是曾接受过实体器官移植。体征是最常见的症状,83.7%的患者有体征,70.4%的病例有发热症状。27.6%的患者出现败血症。该组患者中最常见的实验室异常是血小板减少,占 81.6%,贫血、白细胞减少和白细胞增多分别占 75.5%、55.1% 和 10.2%。63.3%的病例出现肝酶升高。对 64 名患者进行了 H 评分分析,平均值为 209,对 61.2% 的患者进行了骨髓分析。45.9%的HLH患者的主要分离病原体是埃里希氏菌,其次是立克次体(14.3%)和噬细胞嗜血杆菌(12.2%)。值得注意的是,鲍瓦桑病毒感染或莱姆包虫病患者均未出现 HLH。最常见的并发症是35.7%的患者出现急性肾损伤(AKI),22.5%的患者出现休克并伴有多器官功能障碍,20.4%的患者出现脑病/癫痫,16.3%的患者出现呼吸衰竭,7.1%的患者出现心脏并发症。43.9%的患者只接受了抗生素治疗,5.1%的患者只接受了免疫抑制剂治疗。51%的患者同时使用抗生素和免疫抑制剂治疗。62.2%的患者使用了适当的经验性抗生素。在43.9%的蜱传疾病导致的HLH病例中,患者仅接受了抗菌治疗,其中88.4%的患者完全康复,无需接受免疫抑制剂治疗。在我们的研究中,死亡率为 16.3%,接受不恰当或延迟经验疗法的患者预后较差。因此,我们建议对疑似因蜱传疾病导致 HLH 的患者或因诊断延误而导致诊断不确定的患者进行经验性抗生素治疗,以尽量降低死亡率。
{"title":"Hemophagocytic Lymphohistiocytosis (HLH) in Patients with Tick-Borne Illness: A Scoping Review of 98 Cases.","authors":"Dorde Jevtic, Marilia Dagnon da Silva, Alberto Busmail Haylock, Charles W Nordstrom, Stevan Oluic, Nikola Pantic, Milan Nikolajevic, Nikola Nikolajevic, Magdalena Kotseva, Igor Dumic","doi":"10.3390/idr16020012","DOIUrl":"10.3390/idr16020012","url":null,"abstract":"<p><p>Hemophagocytic lymphohistiocytosis (HLH) secondary to tick-borne infections is a rare but potentially life-threatening syndrome. We performed a scoping review according to PRISMA guidelines to systematically analyze the existing literature on the topic. A total of 98 patients were included, with a mean age of 43.7 years, of which 64% were men. Most cases, 31%, were reported from the USA. Immunosuppression was present in 21.4%, with the most common cause being previous solid organ transplantation. Constitutional symptoms were the most common, observed in 83.7% of the patients, while fever was reported in 70.4% of cases. Sepsis was present in 27.6%. The most common laboratory abnormalities in this cohort were thrombocytopenia in 81.6% of patients, while anemia, leukopenia, and leukocytosis were observed in 75.5%, 55.1%, and 10.2%, respectively. Liver enzyme elevation was noted in 63.3% of cases. The H-score was analyzed in 64 patients, with the mean value being 209, and bone marrow analysis was performed in 61.2% of patients. <i>Ehrlichia</i> spp. was the main isolated agent associated with HLH in 45.9%, followed by <i>Rickettsia</i> spp. in 14.3% and <i>Anaplasma phagocytophilum</i> in 12.2%. Notably, no patient with Powassan virus infection or Lyme borreliosis developed HLH. The most common complications were acute kidney injury (AKI) in 35.7% of patients, shock with multiple organ dysfunction in 22.5%, encephalopathy/seizure in 20.4%, respiratory failure in 16.3%, and cardiac complications in 7.1% of patients. Treatment included antibiotic therapy alone in 43.9%, while 5.1% of patients were treated with immunosuppressants alone. Treatment with both antibiotics and immunosuppressants was used in 51% of patients. Appropriate empiric antibiotics were used in 62.2%. In 43.9% of cases of HLH due to tick-borne disease, patients received only antimicrobial therapy, and 88.4% of those recovered completely without the need for immunosuppressive therapy. The mortality rate in our review was 16.3%, and patients who received inappropriate or delayed empiric therapy had a worse outcome. Hence, we suggest empiric antibiotic treatment in patients who are suspected of having HLH due to tick-borne disease or in whom diagnostic uncertainty persists due to diagnostic delay in order to minimize mortality.</p>","PeriodicalId":13579,"journal":{"name":"Infectious Disease Reports","volume":"16 2","pages":"154-169"},"PeriodicalIF":3.4,"publicationDate":"2024-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10961790/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140206787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Excess Mortality Stratified by Age and Sex for Croatia and Croatian Counties during the 2020-2021 COVID-19 Pandemic. 2020-2021 年 COVID-19 大流行期间克罗地亚和克罗地亚各县按年龄和性别分层的超额死亡率。
IF 3.2 Q2 INFECTIOUS DISEASES Pub Date : 2024-02-20 DOI: 10.3390/idr16020011
Mara Šošić, Zvonimir Boban, Marijan Erceg, Nataša Boban

Excess mortality is often used to estimate the effect of a certain crisis on the population. It is defined as the number of deaths during a crisis exceeding the expected number based on historical trends. Here, we calculated excess mortality due to the COVID-19 pandemic for Croatia in the 2020-2021 period. The excess was calculated on the national and county level for different age and sex categories. In addition to the absolute number, the excess mortality was also expressed as a ratio of excess deaths to the predicted baseline and excess mortality rate. We showed that using both measures is necessary to avoid incorrect conclusions. The estimated excess mortality on the national level was 14,963, corresponding to an excess percentage of 14.3%. With respect to sex, there was a higher excess mortality rate for men compared to women. An exponential relationship was observed between age and the excess mortality rate.These trends wee representative of most counties as well, with large variations in the magnitude of the effect. However, there were also exceptions to the general rule. The reasons for these deviations were discussed in terms of between-county differences in demographic structure, population density and special events that took place during the pandemic.

超额死亡率通常用于估计某一危机对人口的影响。它被定义为危机期间的死亡人数超过基于历史趋势的预期人数。在此,我们计算了 2020-2021 年克罗地亚因 COVID-19 大流行而导致的超额死亡率。超额死亡率按不同年龄和性别类别在国家和县一级进行计算。除绝对数字外,超额死亡率还表示为超额死亡人数与预测基线死亡率和超额死亡率的比率。我们的研究表明,为了避免得出错误的结论,有必要同时使用这两种测量方法。估计全国超额死亡率为 14 963 例,相当于 14.3% 的超额百分比。在性别方面,男性的超额死亡率高于女性。年龄与超额死亡率之间呈指数关系。这些趋势在大多数县也具有代表性,但影响程度差异很大。然而,一般规律也有例外。讨论了造成这些偏差的原因,包括县与县之间在人口结构、人口密度和大流行期间发生的特殊事件方面的差异。
{"title":"Excess Mortality Stratified by Age and Sex for Croatia and Croatian Counties during the 2020-2021 COVID-19 Pandemic.","authors":"Mara Šošić, Zvonimir Boban, Marijan Erceg, Nataša Boban","doi":"10.3390/idr16020011","DOIUrl":"10.3390/idr16020011","url":null,"abstract":"<p><p>Excess mortality is often used to estimate the effect of a certain crisis on the population. It is defined as the number of deaths during a crisis exceeding the expected number based on historical trends. Here, we calculated excess mortality due to the COVID-19 pandemic for Croatia in the 2020-2021 period. The excess was calculated on the national and county level for different age and sex categories. In addition to the absolute number, the excess mortality was also expressed as a ratio of excess deaths to the predicted baseline and excess mortality rate. We showed that using both measures is necessary to avoid incorrect conclusions. The estimated excess mortality on the national level was 14,963, corresponding to an excess percentage of 14.3%. With respect to sex, there was a higher excess mortality rate for men compared to women. An exponential relationship was observed between age and the excess mortality rate.These trends wee representative of most counties as well, with large variations in the magnitude of the effect. However, there were also exceptions to the general rule. The reasons for these deviations were discussed in terms of between-county differences in demographic structure, population density and special events that took place during the pandemic.</p>","PeriodicalId":13579,"journal":{"name":"Infectious Disease Reports","volume":"16 2","pages":"142-153"},"PeriodicalIF":3.2,"publicationDate":"2024-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10885044/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139931009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Infectious Disease Reports
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1